A new effective alternative for the control of Porcine Reproductive and Respiratory Syndrome (PRRS) – the most costly disease in pig production – was introduced by Hipra
Unistrain PRRS was presented in the framework of the European Symposium of Porcine Health Management 2013 (ESPHM). More than one hundred of swine veterinarians from Spain, Germany, United Kingdom, Belgium, Holland, France, Italy, Poland, Portugal, Greece and Russia, attended the ” Unistrain PRRS Meeting” that took place in the castle of Edinburgh, on 21 May.
The presentation began with the testimonials of veterinary experts and consultants of swine of international prestige, who gave his point of view regarding the present and future of PRRS. Then safety and efficacy tests conducted with Unistrain PRRS through the testimonial of the R&D of Hipra team, finally showing the process of production of vaccines in Hipra, opening the doors of the company’s facilities. The act was introduced by Isaac Rodríguez, Product manager of the vaccine.
David Nogareda, president and CEO of the company, closed the event stressing the commitment to Hipra becoming the Reference in Prevention in Animal Health.
This meeting is part of the launch campaign of Unistrain PRRS, which began in April and will last until the end of June in all European Union countries.
"*" indicates required fields
Notifications
It's your legal right to choose which information a website may store and have access to. With your permission, we and our third-party partners (19) store and/or access information on a device, such as unique identifiers in cookies and browsing data to collect and process personal data.
We and our partners do the following data processing:
Store and/or access information on a device, Advertising based on limited data and advertising measurement, Personalised content, content measurement, audience research, and services development
If you accept any or all of these, you will have agreed to this website's use of cookies for these purposes. You may also choose to refuse consent, but certain personalized features of the site won't be available to you.